Unicycive Therapeutics, Inc.(UNCY)Earnings, Financials & Key RatiosUnicycive Therapeutics, Inc. (UNCY) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on external capital to fund a $7.5 million average quarterly operating loss, combined with a lack of commercial revenue, presents a binary regulatory risk that outweighs current valuation multiples.
Unicycive Therapeutics, Inc. (UNCY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Unicycive Therapeutics, Inc. (UNCY) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.54vs $0.46-17.7% | —vs $11M |
| Q2 2026 | Mar 30, 2026 | $0.32vs $0.50+36.6% | —vs $517,000 |
| Q4 2025 | Nov 12, 2025 | $0.39vs $0.59+33.9% | — |
| Q3 2025 | Aug 14, 2025 | $0.52vs $0.70+25.7% | — |
Recent stock market news and headlines for Unicycive Therapeutics, Inc. (UNCY)
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.
Key metrics vs top competitors for Unicycive Therapeutics, Inc. (UNCY)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.36 | $1.28B | -3.21 | — | — | -141.14% | — | |
| $86.55 | $12.19B | -7094.26 | 23258.15% | -48.38% | -55.09% | — | |
| $3.46 | $14.98M | -3.17 | 3.7% | -264.73% | -62.1% | — | |
| $5.60 | $22.1M | -3.73 | -31.76% | -7.98% | -15.41% | — | |
| $2.47 | $13.45M | -1.46 | -82.35% | -571.1% | -66.69% | — | |
| $73.15 | $1.43B | -7.52 | -43.89% | -284.18% | -87% | — |
Unicycive Therapeutics, Inc. (UNCY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Unicycive Therapeutics, Inc. (UNCY) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 12, 2026·SEC
Apr 6, 2026·SEC
Mar 30, 2026·SEC
Get notified when UNCY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Unicycive Therapeutics, Inc. (UNCY) stock FAQ — growth, dividends, profitability & financials explained
Unicycive Therapeutics, Inc. (UNCY) reported a net loss of $39.9M for fiscal year 2025.
Unicycive Therapeutics, Inc. (UNCY) has a return on equity (ROE) of -141.1%. Negative ROE indicates the company is unprofitable.
Unicycive Therapeutics, Inc. (UNCY) had negative free cash flow of $28.7M in fiscal year 2025, likely due to heavy capital investments.
